Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 20 of 27

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract April 2014

In vitro Antibiotic Susceptibility Profile of Ocular Pathogens - Results from the First ARMOR Canada Surveillance Study

Joseph M Blondeau; Christine M Sanfilippo; Timothy W Morris; Jennifer Deane; Daniel F Sahm

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):2840.

ARVO Annual Meeting Abstract April 2014

Influence of Buffering Systems on Acanthamoeba Encystment Following Prolonged Storage with Experimental Formulations and a Novel Hydrogen Peroxide-based Disinfecting Solution

Shawn C Lynch; Christopher Kovacs; Kimberly A Millard; Suzanne F Groemminger; Timothy W Morris

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):4645.

ARVO Annual Meeting Abstract April 2014

Besifloxacin Ophthalmic Suspension, 0.6% Compared with Gatifloxacin Ophthalmic Solution, 0.3% for the Treatment of Bacterial Conjunctivitis in Neonatal Patients

Tuyen Ong; Catherine Allaire; Timothy W Morris; Baldo Sforzolini

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5790.

ARVO Annual Meeting Abstract April 2014

Simultaneous Determination of the Rate of Disinfection and Peroxide Neutralization of a Novel Hydrogen Peroxide Disinfecting System

Deborah McGrath; Kimberly A Millard; Damien Cordero; Timothy W Morris

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):6052.

ARVO Annual Meeting Abstract April 2014

Antibiotic Resistance Profile of Ocular Pathogens - An Update from the 2013 US ARMOR Surveillance Study

Christine M Sanfilippo; Timothy W Morris; Jennifer Deane; Deborah C Draghi; Daniel F Sahm

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):6281.

ARVO Annual Meeting Abstract March 2012

Strain ST448 Causes the Majority of Pneumococcal Conjunctivitis Cases

Christine M. Sanfilippo; Wolfgang Haas; Christine K. Hesje; Timothy W. Morris

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):83.

ARVO Annual Meeting Abstract March 2012

Clinical Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% Against Less Common Conjunctivitis Pathogens of Ophthalmic Interest

Timothy L. Comstock; Heleen H. DeCory; Lynne S. Gearinger; Timothy W. Morris

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):4007.

ARVO Annual Meeting Abstract March 2012

Evaluation of Acanthamoeba Encystment for a Novel One-Step Hydrogen Peroxide Disinfecting Solution and Comparator Peroxide Disinfecting Solutions

Shawn C. Lynch; Christopher J. Kovacs; Joseph G. Carr; Matthew A. Dehmler; Kimberly A. Millard; Michael J. Schoene; Suzanne F. Groemminger; Timothy W. Morris

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6080.

ARVO Annual Meeting Abstract March 2012

Regimen Testing of a Novel One-Step Hydrogen Peroxide Disinfecting Solution and Comparators with Soft Contact Lenses and Ocular Clinical Isolates

Jessica M. Burger; Todd H. Bassage; Arthur J. Principe; Deborah McGrath; Patricia A. Walsh; Timothy W. Morris

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6083.

ARVO Annual Meeting Abstract March 2012

Pharmacodynamic Analysis of Hydrogen Peroxide Solution Disinfection Efficacy in One-Step Peroxide Neutralizing Lens Cases

Timothy W. Morris; Damien W. Cordero; Deborah McGrath; Suzanne F. Groemminger; Kimberly A. Millard

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6084.

ARVO Annual Meeting Abstract March 2012

Antibiotic Resistance Profile of Ocular Pathogens - An Update from the ARMOR 2011 Surveillance Study

Wolfgang Haas; Jennifer Deane; Timothy W. Morris; Daniel F. Sahm

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6195.

ARVO Annual Meeting Abstract March 2012

Microbiological Eradication Rates with BID or TID Dosing of Besifloxacin Ophthalmic Suspension, 0.6% in Bacterial Conjunctivitis Clinical Trials from 2004 - 2010

Kirk Bateman; Timothy L. Comstock; Lynne S. Gearinger; Christine K. Hesje; Christine M. Sanfilippo; Timothy W. Morris

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6198.

ARVO Annual Meeting Abstract March 2012

Biocidal Activity of a Novel One-Step Hydrogen Peroxide Disinfecting Solution and Comparator Peroxide Disinfecting Solutions against Ocular Pathogens Including Multidrug-Resistant Bacteria

Deborah McGrath; Damien W. Cordero; Patricia A. Walsh; Timothy W. Morris

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6212.

ARVO Annual Meeting Abstract March 2012

Ophthalmic Demulcents Associated with Acanthamoeba Encystment in Model Multi-Purpose Lens Care Solutions Do Not Cause Encystment in Model Hydrogen Peroxide Solutions

Joseph G. Carr; Christopher J. Kovacs; Shawn C. Lynch; Matthew A. Dehmler; Kimberly A. Millard; Michael J. Schoene; Suzanne F. Groemminger; Timothy W. Morris

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6215.

ARVO Annual Meeting Abstract March 2012

Clinical efficacy of Besifloxacin Ophthalmic Suspension, 0.6% Against MRSA and MRSE

Heleen H. DeCory; Timothy L. Comstock; Lynne S. Gearinger; Timothy W. Morris

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):1862.

ARVO Annual Meeting Abstract April 2011

An Axenic Tetrazolium Dye Based Method for Enumeration of Surviving Acanthamoeba Trophozoites After Treatment With Disinfecting Solutions

Shawn C. Lynch; Christopher J. Kovacs; Joseph G. Carr; Wolfgang Haas; Matthew A. Dehmler; Michael J. Schoene; Timothy W. Morris

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):5831.

ARVO Annual Meeting Abstract April 2011

Microbiological Eradication of Bacterial Conjunctivitis Isolates After Treatment with Besifloxacin Ophthalmic Suspension, 0.6%; Comparison of Dosing Twice Daily for 3 Days and Dosing Three Times Daily for 5 Days

Timothy W. Morris; Lynne S. Gearinger; Wolfgang Haas; Timothy L. Comstock

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):5843.

ARVO Annual Meeting Abstract April 2011

Antibiotic Resistance Trends in Ocular Pathogens - An Update From the ARMOR 2009 and ARMOR 2010 Surveillance Studies

Wolfgang Haas; Chris M. Pillar; Timothy W. Morris; Dan F. Sahm

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):5844.

ARVO Annual Meeting Abstract April 2011

Comparative In Vitro Activity of Ophthalmic Antibacterials Against Ocular Pathogens From a 2009 - 2010 Bacterial Conjunctivitis Clinical Study

Lynne S. Gearinger; Kirk M. Bateman; Christine K. Hesje; Christine M. Sanfilippo; Timothy W. Morris

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):1462.

ARVO Annual Meeting Abstract April 2011

Multi-drug Resistance Among 302 Streptococcus Pneumoniae Bacterial Conjunctivitis Isolates

Christine M. Sanfilippo; Christine K. Hesje; Timothy W. Morris; Wolfgang Haas

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):1489.

1 2

Next 20 Results »

Advertisement